We create innovative treatments for nervous system damage due to injury or disease.
NervGen Pharma
NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. Our lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen is evaluating a new discovery lead, NVG-300, in a preclinical model of ischemic stroke and confirmatory SCI study.
Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury
NervGen is actively recruiting for a landmark Phase 1b/2a proof-of-concept clinical trial of
NVG-291 in individuals with spinal cord injury.
For information regarding recruitment, the call center phone number is +1 (855) 559-6902.
View our Corporate Presentation
Stay Connected
Subscribe to our mailing list to stay up to date
The Latest
News Release
April 3, 2025
NervGen reported its financial and operational results for the full year ended December 31, 2024.
News Release
March 31, 2025
NervGen announced it has initiated an expanded access policy to allow treatment use of the investigational product NVG-291 for those individuals with spinal cord injury who have participated in NervGen clinical trials and meet specific eligibility criteria.
NEWS RELEASE
February 6, 2024
NervGen announced the first subject has been enrolled and dosed in the subacute cohort of its Phase 1b/2a clinical trial evaluating NVG-291 in individuals with SCI.
